



---

**VIRTUAL/TELECONFERENCE  
CONTROLLED SUBSTANCES BOARD  
Virtual, 4822 Madison Yards Way, Madison  
Contact: Tom Ryan (608) 266-2112  
March 14, 2025**

*The following agenda describes the issues that the Board plans to consider at the meeting. At the time of the meeting, items may be removed from the agenda. Please consult the meeting minutes for a description of the actions and deliberations of the Board.*

**AGENDA**

**10:00 A.M.**

**OPEN SESSION – CALL TO ORDER – ROLL CALL**

- A. Adoption of Agenda (1-3)**
- B. Approval of Minutes January 10, 2025 (4-6)**
- C. Reminders: Conflicts of Interests, Scheduling Concerns**
- D. Introductions, Announcements and Recognition**
  - 1) Introduction: Lubna Majeed-Haqqi, Medical Examining Board Representative (Succeeds: Gregory Schmeling)
  - 2) Introduction: Steven Leuthner, Medical Examining Board Representative - Alternate (Succeeds: Kris Ferguson)
  - 3) Recognition: Gregory Schmeling, Medical Examining Board Representative (Replaced: 1/15/2025)
  - 4) Recognition: Kris Ferguson, Medical Examining Board Representative – Alternate (Replaced: 1/15/2025)
- E. Administrative Matters – Discussion and Consideration**
  - 1) Department, Staff, and Board Updates
  - 2) Board Members – Term Expiration Dates
    - a. Barman, Subhadeep – 5/1/2019
    - b. Bellay, Yvonne – DATCP Representative
    - c. Bloom, Alan – 5/1/2020
    - d. Eberhardy, Cullen – AG Representative
    - e. Englebert, Doug – DHS Representative
    - f. Gundersen, David – Dentistry Examining Board Representative
    - g. Kane, Amanda – Board of Nursing Representative
    - h. Majeed-Haqqi, Lubna – Medical Examining Board Representative
    - i. Weitekamp, John – Pharmacy Examining Board Representative
  - 3) Alternates
    - a. Alton, Troy – Dentistry Examining Board Representative
    - b. Leuthner, Steven – Medical Examining Board Representative
    - c. Weinman, Robert – Board of Nursing Representative

- F. **Administrative Rule Matters – Discussion and Consideration (7-11)**
  - 1) **Affirmative Action Order (8-9)**
    - a. CSB 2.011, Relating to Scheduling 5 Fentanyl-related Substances
  - 2) **Pending and Possible Rulemaking Projects**
    - a. **Rule Projects Chart (10-11)**
  
- G. **Prescription Drug Monitoring Program (PDMP) Updates – Discussion and Consideration (12-19)**
  - 1) **WI ePDMP Operations (13-18)**
    - a. Grant Project: PDMP-BadgerTraCS Data Integration
    - b. Recent and Upcoming Releases
    - c. EHR Integration Status
  - 2) **WI ePDMP Outreach (19)**
  
- H. **DSPS Interdisciplinary Advisory Council Liaison Report – Discussion and Consideration**
  
- I. **Board Member Reports – Discussion and Consideration**
  - 1) Medical Examining Board
  - 2) Dentistry Examining Board
  - 3) Board of Nursing
  - 4) Pharmacy Examining Board
  
- J. Report from the Referral Criteria Work Group – Discussion and Consideration
  
- K. Liaison Reports
  
- L. **Speaking Engagements, Travel, or Public Relations Requests, and Reports (20-21)**
  - 1) Speaking Engagement Request – University of Wisconsin – Madison Cannabis Conference 2025 Request for “Policy and Regulation” Panelist – April 22, 2025, Union South, University of Wisconsin - Madison
  
- M. Deliberation on Special Use Authorizations – Discussion and Consideration
  
- N. Discussion and Consideration of Items Received After Preparation of the Agenda
  - 1) Introductions, Announcements, and Recognition
  - 2) Administrative Matters
  - 3) Election of Officers
  - 4) Appointment of Liaisons and Alternates
  - 5) Delegation of Authorities
  - 6) Informational Items
  - 7) Division of Legal Services and Compliance (DLSC) Matters
  - 8) Education and Examination Matters
  - 9) Credentialing Matters
  - 10) Practice Matters
  - 11) Legislative and Administrative Rule Matters
  - 12) Liaison Reports
  - 13) Public Health Emergencies
  - 14) Appearances from Requests Received or Renewed
  - 15) Speaking Engagements, Travel, or Public Relations Requests, and Reports
  - 16) Consulting with Legal Counsel
  
- O. **Public Comments**

**CONVENE TO CLOSED SESSION to deliberate on cases following hearing (s. 19.85(1)(a), Stats.); to consider licensure or certification of individuals (s. 19.85(1)(b), Stats.); to consider individual histories or disciplinary data (s. 19.85(1)(f), Stats.); and to confer with legal counsel (s. 19.85(1)(g), Stats.).**

P. Deliberation on Special Use Authorizations – Discussion and Consideration

Q. Consulting with Legal Counsel

**RECONVENE TO OPEN SESSION IMMEDIATELY FOLLOWING CLOSED SESSION**

R. Vote on Items Considered or Deliberated Upon in Closed Session if Voting is Appropriate

S. Open Session Items Noticed Above Not Completed in the Initial Open Session

**ADJOURNMENT**

**NEXT MEETING: MAY 9, 2025**

\*\*\*\*\*  
MEETINGS AND HEARINGS ARE OPEN TO THE PUBLIC, AND MAY BE CANCELLED WITHOUT NOTICE.

Times listed for meeting items are approximate and depend on the length of discussion and voting. All meetings are held virtually unless otherwise indicated. In-person meetings are typically conducted at 4822 Madison Yards Way, Madison, Wisconsin, unless an alternative location is listed on the meeting notice. In order to confirm a meeting or to request a complete copy of the board's agenda, please visit the Department website at <https://dps.wi.gov>. The board may also consider materials or items filed after the transmission of this notice. Times listed for the commencement of any agenda item may be changed by the board for the convenience of the parties. The person credentialed by the board has the right to demand that the meeting at which final action may be taken against the credential be held in open session. Requests for interpreters for the hard of hearing, or other accommodations, are considered upon request by contacting the Affirmative Action Officer or reach the Meeting Staff by calling 608-267-7213.

**VIRTUAL/TELECONFERENCE  
CONTROLLED SUBSTANCES BOARD  
MEETING MINUTES  
JANUARY 10, 2025**

**PRESENT:** Subhadeep Barman, Yvonne Bellay, Alan Bloom, Cullen Eberhardy, Doug Englebert, David Gundersen, Amanda Kane, Gregory Schmeling, John Weitekamp

**STAFF:** Tom Ryan, Executive Director; Jameson Whitney, Legal Counsel; Nilajah Hardin, Administrative Rules Coordinator; Dialah Azam, Board Administration Specialist; and other DSPS Staff

**CALL TO ORDER**

Doug Englebert, Chairperson, called the meeting to order at 10:00 a.m. A quorum was confirmed with nine (9) members present.

**ADOPTION OF AGENDA**

**MOTION:** Alan Bloom moved, seconded by Amanda Kane, to adopt the Agenda as published. Motion carried unanimously.

**APPROVAL OF MINUTES OF NOVEMBER 8, 2024**

**MOTION:** Yvonne Bellay moved, seconded by David Gundersen, to adopt the Minutes of November 8, 2024, as published. Motion carried unanimously.

**ADMINISTRATIVE MATTERS**

**Election of Officers, Appointments of Liaisons and Alternates, Delegation of Authorities**

*Slate of Officers*

**NOMINATION:** Gregory Schmeling nominated the 2024 slate of officers to continue in 2025. All officers accepted their nominations.

Tom Ryan, Executive Director, called for nominations three (3) times.

The Slate of Officers was elected by unanimous voice vote.

<b>ELECTION RESULTS</b>	
<b>Chairperson</b>	Doug Englebert
<b>Vice Chairperson</b>	Alan Bloom
<b>Secretary</b>	Yvonne Bellay

**Appointment of Liaison and Alternates**

<b>LIAISON APPOINTMENTS</b>	
<b>Special Use Authorization (SUA) Liaison(s)</b>	Alan Bloom, Yvonne Bellay <i>Alternate: Doug Englebert</i>
<b>PDMP Liaison(s)</b>	Subhadeep Barman <i>Alternates: John Weitekamp-Pharmacy Issues &amp; Doug Englebert</i>
<b>Legislative Liaison(s)</b>	Doug Englebert <i>Alternates: John Weitekamp</i>
<b>SCAODA Representative</b>	Subhadeep Barman <i>Alternate: Doug Englebert</i>
<b>Referral Criteria Workgroup</b>	Doug Englebert, John Weitekamp, Subhadeep Barman, Amanda Kane <i>Alternate: Troy Alton</i>
<b>Interdisciplinary Advisory Council</b>	Doug Englebert <i>Alternate: Alan Bloom</i>

**Delegation of Authorities**

**Delegation to Approve Annual Evaluation Report**

**MOTION:** Alan Bloom moved, seconded by Doug Englebert, to authorize the Chairperson (or, in the absence of the Chairperson, the highest-ranking officer or longest serving Board member in that succession) to review and approve the annual evaluation report required by Wis. Stat. § 961.36(3) for filing with the Legislature. Motion carried unanimously.

**Delegation to Handle Administrative Rule Matters**

**MOTION:** Amanda Kane moved, seconded by John Weitekamp, to delegate authority to the Chairperson (or, in the absence of the Chairperson, the highest-ranking officer or longest serving Board member in that succession), to act on behalf of the Board regarding administrative rule matters between meetings. Motion carried unanimously.

**Review and Approval of 2024 Delegations including new modifications**

**MOTION:** Amanda Kane moved, seconded by Cullen Eberhardy, to reaffirm all delegation motions made in 2024, as reflected in the January 10, 2025 agenda materials, which were not otherwise modified or amended during the January 10, 2025 meeting. Motion carried unanimously.

## ADMINISTRATIVE RULE MATTERS

### Scope Statement:

#### *CSB 2.010, Relating to Scheduling Ethylphenidate*

**MOTION:** Subhadeep Barman moved, seconded by Alan Bloom, to approve the Scope Statement creating CSB 2.010, Relating to Scheduling Ethylphenidate, for submission to the Department of Administration and Governor's Office and for publication. Additionally, the Board authorizes the Chairperson to approve the Scope Statement for implementation no less than 10 days after publication. If the Board is directed to hold a preliminary public hearing on the Scope Statement, the Chairperson is authorized to approve the required notice of hearing. Motion carried unanimously.

### Preliminary Rule Draft:

#### *CSB 2.009, Relating Scheduling 2 Synthetic Benzimidazole-Opioids*

**MOTION:** Subhadeep Barman moved, seconded by Yvonne Bellay, to approve the preliminary rule draft of CSB 2.009, Relating to Scheduling 2 Synthetic Benzimidazole-opioids, for posting for economic impact comments and submission to the Clearinghouse. Motion carried unanimously.

### Final Rule and Legislative Report:

#### *CSB 2.006, Relating to Scheduling 5 Synthetic Cannabinoids*

#### *CSB 2.007, Relating to Scheduling ADB-BUTINACA, $\alpha$ -PiHP, and 3-MMC*

#### *CSB 2.008, Relating to Scheduling 2-methyl AP-237*

**MOTION:** Subhadeep Barman moved, seconded by David Gundersen, to approve the Legislative Report and Draft for the following rules for submission to the Governor's Office and Legislature:

- CSB 2.006, Relating to Scheduling 5 Synthetic Cannabinoids
- CSB 2.007, Relating to Scheduling ADB-BUTINACA,  $\alpha$ -PiHP, and 3-MMC
- CSB 2.008, Relating to Scheduling 2-methyl AP-237


Motion carried unanimously.

## ADJOURNMENT

**MOTION:** David Gundersen moved, seconded by John Weitekamp, to adjourn the meeting. Motion carried unanimously.

The meeting adjourned at 10:56 a.m.

**State of Wisconsin  
Department of Safety & Professional Services  
AGENDA REQUEST FORM**

<b>1) Name and title of person submitting the request:</b> Nilajah Hardin Administrative Rules Coordinator		<b>2) Date when request submitted:</b> 03/03/25 <small>Items will be considered late if submitted after 12:00 p.m. on the deadline date which is 8 business days before the meeting</small>	
<b>3) Name of Board, Committee, Council, Sections:</b> Controlled Substances Board			
<b>4) Meeting Date:</b> 03/14/25	<b>5) Attachments:</b> <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	<b>6) How should the item be titled on the agenda page?</b> Administrative Rule Matters – Discussion and Consideration 1. Affirmative Action Order: a. CSB 2.011, Relating to Scheduling 5 Fentanyl-related Substances 2. Pending or Possible Rulemaking Projects a. Rule Projects Chart	
<b>7) Place Item in:</b> <input checked="" type="checkbox"/> Open Session <input type="checkbox"/> Closed Session	<b>8) Is an appearance before the Board being scheduled?</b> <i>(If yes, please complete <a href="#">Appearance Request</a> for Non-DSPS Staff)</i> <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	<b>9) Name of Case Advisor(s), if required:</b> N/A	
<b>10) Describe the issue and action that should be addressed:</b> Review and take action on Scope Statement, Preliminary Rules Drafts, and Final Rule Drafts.  Attachments: <ul style="list-style-type: none"> <li>Affirmative Action Order – CSB 2.011</li> <li>Rule Projects Chart</li> </ul> (All Board Rule Projects can be Viewed Here if Needed: <a href="https://dsps.wi.gov/Pages/RulesStatutes/PendingRules.aspx">https://dsps.wi.gov/Pages/RulesStatutes/PendingRules.aspx</a> )			
<b>11) Authorization</b>			
 Signature of person making this request		03/03/25 Date	
Supervisor (if required)		Date	
Executive Director signature (indicates approval to add post agenda deadline item to agenda)    Date			
<b>Directions for including supporting documents:</b> 1. This form should be attached to any documents submitted to the agenda. 2. Post Agenda Deadline items must be authorized by a Supervisor and the Policy Development Executive Director. 3. If necessary, provide original documents needing Board Chairperson signature to the Bureau Assistant prior to the start of a meeting.			

STATE OF WISCONSIN  
CONTROLLED SUBSTANCES BOARD

---

IN THE MATTER OF RULE-MAKING : AFFIRMATIVE ACTION  
PROCEEDINGS BEFORE THE : ORDER OF THE  
CONTROLLED SUBSTANCES BOARD : CONTROLLED SUBSTANCES BOARD

---

FINDINGS

1. On December 30, 2024, the Department of Justice, Drug Enforcement Administration published its temporary scheduling order in the Federal Register to extend the temporary scheduling of the following 7 fentanyl related substances in schedule I of the federal Controlled Substances Act:

- *Para*-chlorofentanyl
- *Ortho*-chlorofentanyl
- *Meta*-fluorofuranyl fentanyl
- *Ortho*-methylcyclopropyl fentanyl
- *Beta*-methylacetyl fentanyl
- Tetrahydrothiofuranyl fentanyl
- *Para*-fluoro valeryl fentanyl

The scheduling action is effective December 31, 2024.

2. The Controlled Substances Board did not receive an objection to similarly listing the above 7 fentanyl related substances as schedule I controlled substances under ch. 961, Stats. within 30 days of the date of publication in the federal register of the final order listing the above 7 fentanyl related substances as schedule I controlled substances.

3. The Controlled Substances Board will promulgate a final rule, without making the determinations or findings required by ss. 961.11(1), (1m), (1r) and (2) or s. 961.19 and omitting the notice of proposed rulemaking, listing the above 7 fentanyl related substances as schedule I controlled substances.

ORDER

Pursuant to s. 961.11 (4), Stats., the Controlled Substances Board by affirmative action similarly treats the above 7 fentanyl related substances under chapter 961, Stats. by creating the following:

**CSB 2.005 Addition of 7 Fentanyl Related Substances to Schedule I. (1)** Section 961.14 (2) (nd) 8m, 12p, 16h, 16q, 16r, 17d, and 18m are created to read:

961.14 (2) (nd) 8m. Beta-methylacetyl fentanyl (N-phenyl-N-(1-(2-phenylpropyl)piperidin-4-yl)acetamide);

12p. Meta-fluorofuranyl fentanyl (N-(3-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)furan-2-carboxamide);



16h. Ortho-chlorofentanyl (N-(2-chlorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide);

16q. Ortho-methylcyclopropyl fentanyl (N-(2-methylphenyl)-N-(1-phenethylpiperidin-4-yl)cyclopropanecarboxamide);

16r. Para-chlorofentanyl (N-(4-chlorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide);

17d. Para-fluoro valeryl fentanyl (N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)pentanamide);

18m. Tetrahydrothiofuranyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenyltetrahydrothiophen-2-carboxamide);

This order shall become effective upon publication in the Administrative Register. The order expires upon promulgation of a final rule.

Dated \_\_\_\_\_

\_\_\_\_\_  
Doug Englebert, Chair  
Controlled Substances Board

**Controlled Substances Board**  
**Rule Projects (updated 03/03/25)**

CH Rule Number	Scope Number	Scope Expiration Date	Code Chapter Affected	Relating Clause	Stage of Rule Process	Next Step
24-004	053-23	02/07/2026	CSB 2.98	Excluding [ <sup>18</sup> F] FP-CIT	Legislative Review	Adoption Order Review at a Future Meeting
24-005	054-23	02/07/2026	CSB 2.99	Scheduling Mesocarb	Legislative Review	Adoption Order Review at a Future Meeting
24-023	078-23	04/23/2026	CSB 2.001	Scheduling Methiopropamine	Legislative Review	Adoption Order Review at a Future Meeting
24-024	079-23	04/23/2026	CSB 2.002	Excluding Fenfluramine	Legislative Review	Adoption Order Review at a Future Meeting
24-048	001-24	07/02/2026	CSB 2.003	Transferring Flualprazolam and Scheduling 4 Other Synthetic Benzodiazepine Substances	Legislative Review	Adoption Order Review at a Future Meeting
24-058	048-24	11/13/2026	CSB 2.004	Scheduling Zuranolone	Legislative Review	Adoption Order Review at a Future Meeting
24-059	049-24	11/13/2026	CSB 2.005	Scheduling 9 Fentanyl Related Substances	Legislative Review	Adoption Order Review at a Future Meeting
24-083	086-24	02/05/2027	CSB 2.006	Scheduling 5 Synthetic Cannabinoids	Legislative Review	Submission for Governor Approval and Legislative Review
24-084	087-24	02/05/2027	CSB 2.007	Scheduling ADB-BUTINANCA, $\alpha$ -PiHP, and 3- MMC	Legislative Review	Submission for Governor Approval and Legislative Review
24-085	088-24	02/05/2027	CSB 2.008	Scheduling 2-methyl AP-237	Legislative Review	Submission for Governor Approval and Legislative Review
Not Assigned Yet	113-24	06/02/2027	CSB 2.009	Scheduling 2 Synthetic Benzimidazole-Opioids	EIA Comment Period and Fiscal Estimate	Submission for Clearinghouse Review
Not Assigned Yet	Not Assigned Yet	Not Assigned Yet	CSB 2.010	Scheduling Ethylphenidate	Scope Statement Pending Publication	Preliminary Public Hearing or Scope Implementation
Not Assigned Yet	Not Assigned Yet	Not Assigned Yet	CSB 2.011	Scheduling 7 Fentanyl-related Substances	Affirmative Action Order Reviewed at 3/14/25 Meeting	Affirmative Action Order Approval and Publication in Administrative Register

**Controlled Substances Board  
Rule Projects (updated 03/03/25)**

<b>CH Rule Number</b>	<b>Scope Number</b>	<b>Scope Expiration Date</b>	<b>Code Chapter Affected</b>	<b>Relating Clause</b>	<b>Stage of Rule Process</b>	<b>Next Step</b>
24-013	095-22	05/21/2025	CSB 4	National Provider Identifier Requirement	Legislative Review	Adoption Order Review at a Future Meeting
24-033	055-23	02/07/2026	CSB 4	Monitored Prescription Drug History Reports	Legislative Review	Adoption Order Review at a Future Meeting
24-060	072-24	08/12/2026	CSB 4	Mail Delivered Prescriptions	Legislative Review	Adoption Order Review at a Future Meeting

**State of Wisconsin  
Department of Safety & Professional Services**

**AGENDA REQUEST FORM**

<b>1) Name and title of person submitting the request:</b> Marjorie Liu Program Lead, PDMP		<b>2) Date when request submitted:</b> 03/04/2025 <small>Items will be considered late if submitted after 12:00 p.m. on the deadline date which is 8 business days before the meeting</small>														
<b>3) Name of Board, Committee, Council, Sections:</b> Controlled Substances Board																
<b>4) Meeting Date:</b> 03/14/2025	<b>5) Attachments:</b> <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	<b>6) How should the item be titled on the agenda page?</b> Prescription Drug Monitoring Program (PDMP) Updates – Discussion and Consideration														
<b>7) Place Item in:</b> <input checked="" type="checkbox"/> Open Session <input type="checkbox"/> Closed Session	<b>8) Is an appearance before the Board being scheduled?</b> <i>(If yes, please complete <a href="#">Appearance Request</a> for Non-DSPP Staff)</i>  <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	<b>9) Name of Case Advisor(s), if required:</b>														
<b>10) Describe the issue and action that should be addressed:</b> 1. WI ePDMP Operations a. Grant Project: PDMP-BadgerTraCS Data Integration b. Recent and Upcoming Releases c. EHR Integration Status 2. WI PDMP Outreach																
<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%; border-bottom: 1px solid black;"> <b>11)</b>  <i>Marjorie Liu</i> </td> <td style="width: 40%; border-bottom: 1px solid black; text-align: center;"> <b>Authorization</b> </td> <td style="width: 30%; border-bottom: 1px solid black; text-align: right;">                     March 4, 2025                 </td> </tr> <tr> <td style="border-bottom: 1px solid black;">                     Signature of person making this request                 </td> <td colspan="2" style="border-bottom: 1px solid black; text-align: right;">                     Date                 </td> </tr> <tr> <td style="border-bottom: 1px solid black;">                     Supervisor (if required)                 </td> <td colspan="2" style="border-bottom: 1px solid black; text-align: right;">                     Date                 </td> </tr> <tr> <td colspan="3" style="border-bottom: 1px solid black;">                     Executive Director signature (indicates approval to add post agenda deadline item to agenda)                 </td> <td style="border-bottom: 1px solid black; text-align: right;">                     Date                 </td> </tr> </table>				<b>11)</b> <i>Marjorie Liu</i>	<b>Authorization</b>	March 4, 2025	Signature of person making this request	Date		Supervisor (if required)	Date		Executive Director signature (indicates approval to add post agenda deadline item to agenda)			Date
<b>11)</b> <i>Marjorie Liu</i>	<b>Authorization</b>	March 4, 2025														
Signature of person making this request	Date															
Supervisor (if required)	Date															
Executive Director signature (indicates approval to add post agenda deadline item to agenda)			Date													
<b>Directions for including supporting documents:</b> 1. This form should be attached to any documents submitted to the agenda. 2. Post Agenda Deadline items must be authorized by a Supervisor and the Policy Development Executive Director. 3. If necessary, provide original documents needing Board Chairperson signature to the Bureau Assistant prior to the start of a meeting.																

# 2023-2025 Development and Release Summary

Updated 3.3.2025

Release Date	Description
<b>Completed</b>	
<b>R33.16 February 2025</b>	<p>Data Analytics Updates:</p> <ul style="list-style-type: none"> <li>• MME Conversion Factors updates</li> <li>• Buprenorphine exclusion rules applied to automated reporting of prescribing reports</li> </ul> <p>User Interface Updates</p> <ul style="list-style-type: none"> <li>• Healthcare Professionals - MME Calculator &amp; Addiction Resource Updates</li> <li>• Investigators - Dispenser Report Request via User Accounts</li> </ul> <p>Administrative workflow updates - NPI added to Pending Account Registration Review</p> <p>Webpage Language Updates: Registration Page, Dashboard charts</p>
<b>R33.15.1 February 2025</b>	Emergency Release to fix errors for out of state queries connecting via PMPi hub
<b>R33.15 January 2025</b>	<p>Data Analytics Updates:</p> <ul style="list-style-type: none"> <li>• New admin tool of adding additional DEA numbers to automate Detailed Prescriber Monitoring Report</li> <li>• Formatting updates on Opioid Practice Summary Report</li> </ul> <p>User Interface Updates:</p> <ul style="list-style-type: none"> <li>• Pharmacy Account data revise/edit screen now with multiple DEAs dropdown selection</li> </ul>
<b>R33.14 January 2025</b>	<p>Updates to online form "Report Suspected Errors in WI ePDMP Date" PDF</p> <p>Pharmacy additional DEA display</p> <p>Increased License Number Character Limits from 7 to 8</p> <p>File Processing Updates - Skipping Duplicate Files</p>
<b>R33.13 December 2024</b>	<p>User Interface:</p> <ul style="list-style-type: none"> <li>• Updated Text on the Delegate Management Screen</li> <li>• Updated Calculations for Daily Prescribing Volume Ranking for Opioids</li> <li>• License Number is no Longer a Required Field for a Medical Coordinator Account</li> </ul> <p>Admin Portal Updates:</p> <ul style="list-style-type: none"> <li>• Added Submission Date to Prescriber Alerts Table</li> <li>• NDC of Dispensed Medications displayed in the prescriber Report</li> <li>• Updated the Prescriber Query Compliance Report</li> </ul>
<b>R33.12 November 2024</b>	<p>ePDMP Webpage Updates: Contact Us info &amp; user registration screen for Medical Coordinator and Researcher</p> <p>Analytics and Reports Updates-</p> <ul style="list-style-type: none"> <li>• Prescriber Monitoring Report Charts Readability</li> <li>• Prescriber Address populated on Dispensing History Details</li> </ul> <p>Administrative Workflow Enhancement: Alert reviewing screen updates</p>

<p><b>R33.11</b> <b>September 2024</b></p>	<p>Non – HCP Alert Displays on Requested Reports Detailed Prescriber Monitoring Report Rework Updated Quarterly CSB Reports Prescriber Address Visible on Patient Report Table</p>
<p><b>R33.10</b> <b>August 2024</b></p>	<p>Automation of Reports:</p> <ul style="list-style-type: none"> <li>• Opioid Prescribing Practice Summary Report Review</li> <li>• Quarterly Statistics for CSB Report Review</li> <li>• Detailed Prescriber Monitoring Report Review</li> <li>• Prescriber Address Populated on UI</li> </ul> <p>EHR Support Partial Refill Review</p>
<p><b>R33.9</b> <b>July 2024</b></p>	<p>Opioid Prescribing Practice Summary Report Review Text Updates in UI Updates to notification emails Prescriber Query Compliance Report update</p>
<p><b>R33.8</b> <b>June 2024</b></p>	<p>Opioid Prescribing Practice Summary Report Review Quarterly CSB Report Review Compound Drug UI Statistic utilization optimizations Addition of email address to non-HCP query requests</p>
<p><b>R33.7</b> <b>May 2024</b></p>	<p>Dispenser Compliance Report Review Submitter/Dispenser Report Review</p>
<p><b>R33.6</b> <b>April 2024</b></p>	<p>System Updates</p> <ul style="list-style-type: none"> <li>• Pending Account Changes UI language</li> <li>• UAT email notification links</li> <li>• Controlled Substance UI language</li> </ul> <p>Updated error messages for Submitters RXCheck 3.1 Update and Patch Statistics Dashboard populate counties' logic EHR Support</p>
<p><b>R33.5</b> <b>March 2024</b></p>	<p>Statistics reporting updates EHR/Epic OAuth Support File Submission Queue processing</p>
<p><b>R33.4</b> <b>February 2024</b></p>	<p>DEA File Updates LicenseE Update – State License Validation Training Materials Update File Processing support EHR support</p>

<p style="text-align: center;"><b>R33.3</b> <b>January 2024</b></p>	<p>LicenseE Update – New User Registration LicenseE Update – User Login Validation PDMP UI Page Text Updates</p> <ul style="list-style-type: none"> <li>• Home Page</li> <li>• Contact Us</li> <li>• Patient History Detail</li> </ul> <p>File Processing Support EHR Support</p>
<p style="text-align: center;"><b>R33.2</b> <b>January 2024</b></p>	<p>Pharmacy Users fixes</p> <ul style="list-style-type: none"> <li>• Zero reports</li> <li>• Revise/Correct/Void</li> </ul> <p>File Processing support EHR support</p>
<p style="text-align: center;"><b>R33.1</b> <b>November 2023</b></p>	<p>Utilization page updates PMPi States Admin Manage Alerts Timeout Patient Matching Updates</p>
<p style="text-align: center;"><b>R33.0</b> <b>November 2023</b></p>	<p>Geocoding Address2 Line rejection Updated Submitter Guide</p>
<p style="text-align: center;"><b>R32.5</b> <b>October 2023</b></p>	<p>File processing support</p>
<p style="text-align: center;"><b>R32.4</b> <b>October 2023</b></p>	<p>EHR Support</p>
<p style="text-align: center;"><b>R32.3</b> <b>October 2023</b></p>	<p>EHR Support</p>
<p style="text-align: center;"><b>R32.2</b> <b>October 2023</b></p>	<p>EHR Support</p>
<p style="text-align: center;"><b>R32.1</b> <b>October 2023</b></p>	<p>Iframe support Epic</p>

<b>R32</b> <b>October 2023</b>	HRG 2020 Grant Release
<b>R31</b> <b>March 2023</b>	Iframe support Epic
<b>R30</b> <b>February 2023</b>	Iframe support Prescriber Practice Metric UI Text updates Maintenance Updates



# WI ePDMP Integration Services Summary

Current as of 3.3.25

Pending Health Systems and EHR Platforms	Status			Notes
Internal Medicine Associates	In discussion			
MECFS Clinic MN	In discussion			
Oak Leaf	In discussion			
Connected Health Systems (61% of monthly patient queries)	Free Pricing Model	Implementation Date	Est. Total # of Users	Notes
Advent Health		03/05/2023	15	
Allina Health	Y	09/18/2023	100	
Ascension Wisconsin				
Aspirus Health Care				
Aurora Health Care	Y	05/08/2024	12,000	
Children's Hospital of Wisconsin	Y	09/01/2022	300	
Clark County	Y			
Clean Slate	Y	09/01/2022	26	
CompuGroup Medical	Y		50	Internal Go-Live in Process
DrFirst				
Froedtert & the Medical College of Wisconsin			100	Pending signed Free agreement
GHC of South Central Wisconsin	Y			
Gundersen Health System			800	Pending signed Free agreement
HealthPartners				
HSHS / Prevea Health	Y	01/01/2023	500	
M Health Fairview	Y	08/01/2022	30	
Marshfield Clinic	Y	09/01/2022	100	
Mayo Clinic				
Mercy Health	Y	08/01/2022	766	
Monroe Clinic				

NOVO Health Technology Group	Y	02/01/2023		
Ochin	Y	12/21/2022	100	
ProHealth Care				
QuadMed, LLC	Y		40	
SSM Health				
Thedacare				Pending signed Free agreement
UnityPoint				
UW Health			4000	
Wisconsin Statewide Health Information Network	Y	09/01/2022	3500	

DrFirst Facilities		
Alay Health Team	Lifescance Health WI	Richland Hospital
Associated Mental Health Consultants	Madison Recovery Center	Rogers Memorial Hospital
Behavioral Health Svcs of Racine Co.	Marshfield Clinic Health System	Sauk Prairie Memorial Hospital
Benjamin S. Gozon MDSC D/B/A Capitol Rehabilitation Clinic	Mental Health Specialty Group PA	Shorewood Behavioral Health
Christian Family Solutions	Mile Bluff Medical Center	Third Eye Health
Door County Memorial Hospital	Milwaukee Medical Associate, SC	Watertown Rainbow Hospice
Dr. Colleen Worth, DNP, APNP	Mindful Healing and Wellness LLC	Wauwatosa Children's Clinic
Empower Recovery	National Medical Groups	Watertown Regional Medical Center
Envision ADHD Clinic	Nova Integrated Care LLC	
FAMILY PSYCHIATRIC CARE, LLC	Oak Medical	
Fort Healthcare	Oral Surgery Associates of Milwaukee	
GI Associates LLC	Orthopedic Hospital of Wisconsin	
Heartland Hospice	Pain Management and Treatment Center	
Jonathan Hoerl PMHNP	Pediatrics Associates	
Kelly Pickens	Reka Furedi MD	

## 2025 WI PDMP Outreach Calendar

MONTH	EVENT	DESCRIPTION	DATES	NOTES
January	Overdose Fatality Review (OFR) State Advisory Group	DSPS Representative; inter-agency advisory board for OFR participating local sites	1/9/2025	Virtual; Quarterly Meeting
February				
March	Bi-Annual RxCheck Governance Board Meeting	Board Member-Participant; Interstate PDMP data exchange discussion	3/18-3/19/2025	San Diego, CA
April	Overdose Fatality Review (OFR) Local Community Meeting	PDMP Presentation; Portage County OFR Team Meeting	4/1/2025	Virtual
	Overdose Fatality Review (OFR) State Advisory Group	DSPS Representative; inter-agency advisory board for OFR participating local sites	4/10/2025	Virtual; Quarterly Meeting
May	Opioids, Stimulants, and Trauma Summit	Information Booth; participants	5/6-5/8/2025	Wisconsin Dells
June	PMP InterConnect Steering Committee Meeting	Participant; Annual national meeting for PDMP administrators organized by National Association of Boards of Pharmacy (NABP)	6/23-6/24/2025	Mount Prospect, IL
July	Overdose Fatality Review (OFR) State Advisory Group	DSPS Representative; inter-agency advisory board for OFR participating local sites	7/10/2025	Virtual; Quarterly Meeting
August				
September				
October	Overdose Fatality Review (OFR) State Advisory Group	DSPS Representative; inter-agency advisory board for OFR participating local sites	10/9/2025	Virtual; Quarterly Meeting
	NASCSA Conference (National Association of State Controlled Substances Authorities)	Participant; annual national meeting organized by NASCSA for government controlled substances authority, PDMP and healthcare professionals	10/20-10/23/2025	New Orleans, LA
November				
December				

**State of Wisconsin  
Department of Safety & Professional Services**

**AGENDA REQUEST FORM**

2) Name and title of person submitting the request: Doug Englebert, Board Chair		2) Date when request submitted: 3/3/2025 Items will be considered late if submitted after 12:00 p.m. on the deadline date which is 8 business days before the meeting	
3) Name of Board, Committee, Council, Sections: Controlled Substances Board			
4) Meeting Date: 3/14/2025	5) Attachments: <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	6) How should the item be titled on the agenda page? Speaking Engagement Request – University of Wisconsin – Madison Cannabis Conference 2025 Request for “Policy and Regulation” Panelist – April 22, 2025, Union South, University of Wisconsin - Madison	
7) Place Item in: <input checked="" type="checkbox"/> Open Session <input type="checkbox"/> Closed Session	8) Is an appearance before the Board being scheduled? <i>(If yes, please complete <a href="#">Appearance Request</a> for Non-DSPS Staff)</i>  <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	9) Name of Case Advisor(s), if applicable: N/A	
10) Describe the issue and action that should be addressed: Chair Englebert received a request to serve on a panel at this conference. He cannot attend. The invitation is before the Board so others can consider volunteering to serve on the panel.			
11) <b>Authorization</b>			
Signature of person making this request		Date	
Supervisor (Only required for post agenda deadline items)		Date	
Executive Director signature (Indicates approval for post agenda deadline items)		Date	
Directions for including supporting documents: 1. This form should be saved with any other documents submitted to the <a href="#">Agenda Items</a> folders. 2. Post Agenda Deadline items must be authorized by a Supervisor and the Policy Development Executive Director. 3. If necessary, provide original documents needing Board Chairperson signature to the Bureau Assistant prior to the start of a meeting.			



Dear Douglas Englebert,

On behalf of UW-Madison, we humbly request your consideration to serve as a panelist at the first annual [UW-Madison Cannabis Research Conference](#) on April 22, 2025. This inaugural event is presented by the [UW College of Agricultural and Life Sciences](#), [School of Human Ecology](#), [School of Pharmacy](#), [Center for Tobacco Research and Intervention](#), and [Global Health Institute](#) and our theme is, *"From Seed to Society: Cultivating Connections."*

The 2025 UW-Madison Cannabis Conference is a dynamic, multi-disciplinary event aimed at expanding awareness, fostering knowledge exchange, and bridging gaps in cannabis research, education, and policy. The conference brings together researchers across UW-Madison as well as key industry stakeholders to share updates and facilitate collaboration. Attendees will gain valuable insights into the evolving landscape of cannabis science, industry, and regulation through engaging discussions and networking opportunities. This year's conference features presentations and panel discussions with esteemed colleagues from academia, industry, and state agencies focusing on four priority topic areas: agriculture, health and medicine, business and design, and policy and regulation.

**Given your expertise and influential contributions on Wisconsin's Controlled Substances Board, we would be honored to have you join us for this important discussion. Your insights would be invaluable to the dialogue around current and future policies and regulations that shape Wisconsin. The panel will explore key challenges, opportunities, and strategies in policy and regulation, and we are confident your perspective would greatly enrich the conversation. The conference takes place at UW-Madison's Union South, and the "Policy & Regulation Panel" is scheduled for 3:30 – 5:00pm. This session will be co-moderated by Lucas Richert, Professor & George Urdang Chair in Pharmacy History, UW-Madison, and Calyn Ostrowski, Associate Director of Strategic Partnerships & Development, Global Health Institute, UW-Madison.**

Thank you for your consideration. Please reach out to Lucas Richert ([lrichert@wisc.edu](mailto:lrichert@wisc.edu)), if you have any questions or need additional information. We look forward to your response.

Sincerely,

Lucas Richert  
Professor  
School of Pharmacy

Calyn Ostrowski  
Associate Director  
Global Health Institute